载脂蛋白A-I抑制THP-1细胞趋化、粘附、激活及对HDL炎症指数的改善作用
|
摘要
尽管高密度脂蛋白(HDL)的抗炎作用已被广泛接受,但载脂蛋白A-I(ApoA-I)的抗炎作用却了解甚少。本论文在以往研究的基础上,更深入地探讨了ApoA-I的抗炎机制,特别是ApoA-I对于单核细胞与内皮细胞的相互作用、对内毒素(LPS)诱导全身性炎症兔血浆HDL炎症指数的影响。结果显示,ApoA-I能显著减少LPS诱导的THP-1细胞释放单核细胞趋化因子-1(MCP-1)、降低oxLDL诱导的THP-1细胞迁移率(均为P＜0.01);ApoA-I显著降低LPS诱导的THP-1细胞释放可溶性白细胞选择素(sL-Selectin)、可溶性细胞间粘附分子-1(sICAM-1)、可溶性血管细胞粘附分子-1(sVCAM-1)(分别为P＜0.01,P＜0.01,P＜0.05);ApoA-I显著抑制LPS诱导的THP-1细胞表面CD11b和VCAM-1的表达(分别为P＜0.01,P＜0.05);ApoA-I能减少LPS诱导的THP-1细胞膜CD14(mCD14)的表达(P＜0.01),抑制NFκB的核内转位;单次注射ApoA-I能降低LPS诱导的全身性炎症兔血浆HDL的炎症指数,改善HDL的抗炎功能。
结论:ApoA-I能抑制THP-1细胞趋化、粘附、激活,改善血浆HDL炎症指数,发挥抗炎作用。
Whereas the antiinflammatory effects of high density lipoprotein(HDL) are well described,such effects of Apolipoprotein A-I(ApoA-I) are less studied.On the basis of our previous study,we furtherly explored the mechanism of antiinflammatory effects of ApoA-I,and focused especially on the interaction between monocyte and endothelial cells and plasma HDL inflammatory index in LPS-challenged rabbits.The results showed that ApoA-I significantly decreased LPS-induced MCP-1 release of THP-1 cells and oxLDL-induced THP-1 migration ratio(P＜0.01 respectively). ApoA-I significantly decreased sL-selectin,slCAM-1 and sVCAM-1 release of LPS-stimulated THP-1 cells(P＜0.01,P＜0.01,P＜0.05 respectively).Furthermore, ApoA-I significantly inhibited LPS-induced CD11b and VCAM-1 expressions on THP-1 cells(P＜0.01,P＜0.05 respectively).ApoA-I diminished LPS-induced mCD14 expression(P＜0.01) and NFκB nuclear translocation in THP-1 cells.After single dosage treatment of ApoA-I,the value of plasma HDL inflammatory index in LPS-challenged rabbits was improved significantly(P＜0.05).
Conclusions:ApoA-I can inhibit the chemotaxis,adhesion and activation of THP-1 cells and impove plasma HDL inflammatory index with presenting beneficial antiinflammatory effects.
结论:ApoA-I能抑制THP-1细胞趋化、粘附、激活,改善血浆HDL炎症指数,发挥抗炎作用。
Whereas the antiinflammatory effects of high density lipoprotein(HDL) are well described,such effects of Apolipoprotein A-I(ApoA-I) are less studied.On the basis of our previous study,we furtherly explored the mechanism of antiinflammatory effects of ApoA-I,and focused especially on the interaction between monocyte and endothelial cells and plasma HDL inflammatory index in LPS-challenged rabbits.The results showed that ApoA-I significantly decreased LPS-induced MCP-1 release of THP-1 cells and oxLDL-induced THP-1 migration ratio(P＜0.01 respectively). ApoA-I significantly decreased sL-selectin,slCAM-1 and sVCAM-1 release of LPS-stimulated THP-1 cells(P＜0.01,P＜0.01,P＜0.05 respectively).Furthermore, ApoA-I significantly inhibited LPS-induced CD11b and VCAM-1 expressions on THP-1 cells(P＜0.01,P＜0.05 respectively).ApoA-I diminished LPS-induced mCD14 expression(P＜0.01) and NFκB nuclear translocation in THP-1 cells.After single dosage treatment of ApoA-I,the value of plasma HDL inflammatory index in LPS-challenged rabbits was improved significantly(P＜0.05).
Conclusions:ApoA-I can inhibit the chemotaxis,adhesion and activation of THP-1 cells and impove plasma HDL inflammatory index with presenting beneficial antiinflammatory effects.
引文
[1]Ross R.The pathogenesis of atherosclerosis—an update[J].N Engl J Med.1986,314:488-500.
[2]Ross R.Atherosclerosis—an inflammatory disease[J].N Engl J Med.1999,340:115-126.
[3]van Leeuwen HJ,van Beek AP,Dallinga-Thie GM,et al[J].The role of high density lipoprotein in sepsis.Neth J Med.2001,59:102-110.
[4]张慧平.高密度脂蛋白与动脉粥样硬化和冠心病[J].中国动脉硬化杂志.2004,12:733-736.
[5]方微,张慧信,王绿娅.粘附分子、炎症与动脉粥样硬化[J].中国动脉硬化杂志.2002,10:64-66.
[6]Price MJ,Shah PK.New strategies in managing and preventing atherosclerosis:focus on HDL[J].Rev Cardiovasc Med.2002,3:129-137.
[7]Blankenhorn DH,Hodis HN.Atherosclerosis-reversal with therapy[J].West J Med.1993,159:172-179.
[8]Krause BR,Auerbach BJ.Reverse cholesterol transport and future pharmacologi -cal approaches to the treatment of atherosclerosis[J].Curr Opin Investig Drugs.2001,2:375-381.
[9]田庆印.氧化修饰脂蛋白与动脉粥样硬化[J].中国动脉硬化杂志.96,4:149-153.
[10]Wu AH,Hinds CJ,Thiemermann C.High-density lipoproteins in sepsis and septic shock:metabolism,actions,and therapeutic applications[J].Shock.2004,21:210-221.
[11]Murch O,Collin M,Hinds CJ,Yhiemermann C.Lipoproteins in inflammation and sepsis.I.Basic science[J].Intensive Care Med.2007,33:13-24.
[12]Shin WS,Szuba A,Rockson SG.The role of chemokines in human cardiovascular pathology:enhanced biological insights[J].Atherosclerosis.2002,160:91-102.
[13]Krishnaswamy G,Kelley J,Yerra L,et al.Human endothelium as a source of multifunctional cytokines:molecular regulation and possible role in human disease[J].J Interferon Cytokine Res.1999,19:91-104.
[14]Mach F.The role of chemokines in atherosclerosis[J].Curr Atheroscler Rep.2001,3:243-251.
[15]王利民.粘附分子和动脉粥样硬化[J].心血管病学进展.2005,26:494-498.
[16]王克勤.脂蛋白与动脉粥样硬化[M].北京:人民卫生出版社,1995:56.
[17]Puranik R,Bao S,Nobecourt E,et al.Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo[J].Atherosclerosis.2007,196:240-247.
[18]Thaveeratitham P,Plengpanich W,Naen-Udom W,et al.Effects of human apolipoprotein A-I on endotoxin-induced leukocyte adhesion on endothelial cells in vivo and on the growth of Escherichia coli in vitro[J].J Endotoxin Res.2007,13:58-64.
[19]Ma J,Liao XL,Lou B,et al.Role of apolipoprotein A-I in protecting against endotoxin toxicity[J].Acta Biochim Biophys Sin(Shanghai).2004,36:419-424.
[20]Jiao YL,Wu MP.Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid[J].Cytokine.2008,43:83-87
[21]Yan YJ,Li Y,Lou B,et al.Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice[J].Life Sci.2006,79,210-215.
[22]Liao XL,Lou B,Ma J,et al.Neutrophils activation can be diminished by apolipoprotein A-I[J].Life Sci.2005,77:325-335.
[23]Li Y,Dong JB,Wu MP.Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice[J].Eur J Pharmacol.2008,590:417-422.
[24]Gu SS,Shi N,Wu MP.The protective effect of ApolipoproteinA-I on myocardial ischemia-reperfusion injury in rats[J].Life Sci.2007,81:702-709.
[25]Shi N,Wu MP.Apolipoprotein A-I attenuates renal ischemia/reperfusion injury in rats[J].J Biomed Sci.2008,15:577-583.
[26]Lerch PG,F(o|¨)rtsch V,Hodler G,Bolli R.Production and characterization of a reconstituted high density lipoprotein for therapeutic applications[J].Vox Sang.1996,71:155-164.
[27]Ulrich-Merzenich G,Metzner C,Bhonde RR,et al.Simultaneous isolation of endothelial and smooth muscle cells from human umbilical artery or vein and their growth response to low-density lipoproteins[J].In Vitro Cell Dev Biol Anim.2002.38:265-272.
[28]宋今丹,章静波,张世馥,等.组织和细胞培养技术[M].北京:人民卫生出版社,2004:69.
[29]Weibel ER,Palade GE.New cytoplasmic components in arterial endothelia[J].J Cell Biol.1964,23:101-112.
[30]Wagner DD,Olmsted JB,Marder VJ.Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells[J].J Cell Biol.1982,95:355-360.
[31]Haverkate F.Levels of haemostatic factors,arteriosclerosis and cardiovascular disease[J].Vasc Pharm.2002,39:109-112.
[32]Tracy RP,Bovill EG,Yanez D,et al.Fibrinogen and factor Ⅷ,but not factor Ⅶ,are associated with measures of subclinical cardiovascular disease in the elderly:results from the cardiovascular health study[J].Arterioscler Thromb Vasc Biol.1995,15:1269-1279.
[33]Niwa K,Kado T,Sakai J,et al.The effects of a shear flow on the uptake of LDL and acetylated LDL by an EC monoculture and an EC-SMC coculture[J].Ann Biomed Engine.2004,32:537-543.
[34]Niwa K,Sakai J,Watanabe T,et al.Improved arterial wall model by coculturing vascular endothelial and smooth muscle cells[J].In Vitro Cell Dev Biol-Animal.2007,43:17-20.
[35]成安,吴满平,陈佩芳,等.高密度脂蛋白的氧化修饰的特征及对低密度脂蛋白氧化的影响[J].上海医科大学学报.1997,24:167.
[36]余灯广,高秋华,胡锦东,等.TBARS法测定胰岛素口腔喷雾剂中脂质过氧化物研究[J].分析科学学报.2005,21:78-80.
[37]Keiper T,Al-Fakhri N,Chavakis E,et al.The role of junctional adhesion molecule-C(JAM-C) in oxidized LDL-mediated leukocyte recruitment[J].FASEB J.2005,19:2078-2080.
[38]Murphy AJ,Woollard KJ,Hoang A,et al.High-density lipoprotein reduces the human monocyte inflammatory response[J].Arterioscler Thromb Vasc Biol.2008,28:2071-2077.
[39]Cobb RR,Felts KA,McKenzie TC,et al.A benzothiophene-carboxamide is a potent inhibitor of IL-1β induced VCAM-1 gene expression in human endothelial cells[J].FEBS Lett.1996,382:323-326.
[40]Tamai R,Sugawara S,Takeuchi O,et al.Synergistic effects of lipopolysaccharide and interferon-γ in inducing interleukin-8 production in human monocytic THP-1 cells is accompanied by up-regulation of CD14,Toll-like receptor 4,MD-2 and MyD88 expression[J].J Endotoxin Res.2003,9:145-153.
[41]Kimpinski K,Jelinski S,Mearow K.The anti-p75 antibody,MC192,and brain -derived neurotrophic factor inhibit nerve growth factor-dependent neurite growth from adult sensory neurons[J].Neuroscience.1999,93:253-263.
[42]彭世国,胡定远,余建华.沉淀剂浓度对测定高密度脂蛋白胆固醇的影响[J].华西医学.1999,14:473-474.
[43]Navab M,Hama SY,Hough GP,et al.A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids[J].J Lipid Res.2001,8:1308-1317.
[44]Ansell B J,Navab M,Hama S,et al.Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment[J].Circulation.2003,108:2751-2756.
[45]Fruebis J,Gonzalez V,Silvetre M,et al.Effect ofp robucol treatment on gene expression of VCAM-1,MCP-1,and M-CSF in the aortic wall of LDL receptordeficient rabbits during early atherogenesis[J].Arterioscler Thromb Vasc Biol.1997,17:1289-1302.
[46]蔡雪黎,杨德业.炎性反应因子在动脉粥样硬化中的角色[J].中国临床实用医学.2007,1:79-82.
[47]周兴建,蒋绿芝.MCP-1与胰岛素抵抗和2型糖尿病的关系[J].国际内分泌代谢杂志.2006,26:99-101.
[48]杨简.细胞黏附分子和动脉粥样硬化[J].医学综述.2006,12:1307-1309.
[49]Bella J,Kolatkar PR,Marlor CW,et al.The structure of the two aminoterminal domains of human intercellular adhesion molecule21 suggests how it functions as a rhinovirus receptor[J].Virus Res.1999,62:107-117.
[50]Sakai A,Kume N,Nishi E,et al.P-selectin and vascular cell adhesion molecule-1 are focally expression in aortas of hypercholesterolemic rabbits before intimal accumulation of macrophages and T lymphocytes[J].Arterioscler Thromb Vase Biol.1997,1'7:310-316.
[51]Cusack MR,Marber MS,Lambiase PD,et al.Systemic inflammation in unstable angina is the result of myocardial necrosis[J].J Am Coll Cardiol.2002,39:1917-1923.
[52]Babi LS,Moser B,Soler MP,et al.The interleukin-8 receptor B and CXC-chemokines can mediate transendothelial migration of human skin homing T cells[J].Eur J Immunol.1996,26:2056-2059.
[53]Mulvihill NT,Foley JB,Murphy RT,et al.Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules[J].Heart.2001,85:623-625.
[54]张红霞,刘剑刚.动脉粥样硬化发病机制和炎症反应关系研究进展[J].中国心血管杂志.2005,10:385-387
[55]刘兴.脂多糖受体的研究进展[J].国外医学临床生物化学与检验学分册.2001.22:134-137.
[56]陈理华.CD14分子的受体作用及其信号传递[J].国外医学免疫学分册.2000,23:137-140.
[57]张葵.CD14的研究进展及临床意义[J].临床检验杂志.2003,21:367-368.
[58]谢金文,万勇,余为一.CD14分子的研究进展[J].安徽农学通报,2006,12:35
[59]龚建平,韩本立.CD14在LPS介导Kuffer细胞激活中的作用[J].世界华人消化杂志.1999,79:875-877.
[60]Stephan RK,Peter AS,Robert LMl The role of Toll-like receptors in host defense against microbial infection[J].Curr Opin Immunol.2001,13:104-108.
[61]van Amersfoort ES,van Berkel TJ,Kuiper J.Receptors,mediators,and mechanisms involved in bacterial sepsis and septic shock[J].Clin Microbiol Rev.2003,16:379-414.
[62]Miyake K.Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2:unique roles for MD-2[J].Int Immunol Pharmacol.2003,3:119-128.
[63]Parviz AN,Hacker H,Mark R.Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distince cellula rcompartments[J].Eur J Immunol.2002,327:1958-1968.
[64]Normura F,Akashi S,Sakao Y,et al.Endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4expression[J].J Immunol.2000,164:3476-3479.
[65]Lorens E,Mira JP,Frees KL,et al.Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock[J].Arch Intern Med.2002,162:1028-1032
[66]Child NJ,Yang IA,Pulletz MC,et al.Polymorphismsin toll-like receptor 4 and the systemic inflammatory response syndrome[J].Biochem Soc Trans.2003,31:652-653.
[67]Gangloff M,Gay NJ.MD-2:the Toll "gatekeeper" in endotoxin signalling[J]. Trends Biochem Sci.2004,29:294-300.
[68]刘轩,魏育林.LPS受体CD14的最新研究进展[J].解剖科学进.1999,5:1-7.
[69]赵虎,周庭银.CD14的结果与功能[J].免疫学杂志.2000,16:74-76.
[70]徐也鲁.动脉粥样硬化——一种慢性炎症过程[J].中国动脉硬化杂志.2001,9:93-95.
[71]Hosono M,De Boer OJ,Vander-Wal AC,et al.Increased expression of T cell activation markers(CD25,CD26,CD30L and CD69) in atherectomy specimens of atients with unstable angina and acute myocardial infarction[J].Atherosclerosis.2003,168:73-80.
[72]范乐明.动脉粥样硬化炎症机制的再认识[J].中国动脉硬化杂志.2005,13:249-253.
[73]Hernandez-Presa M,Ortego M,Tunon J,et al.Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet[J].Cardiovasc Res.2003,57:168-177.
[74]敖启林,熊密,郝春荣,等.NFκB的活性和iNOS基因表达在低氧性肺动脉高压中的变化[J].中国病理生理杂志.2002,18:903-906.
[75]Kothe H,Dalhoff K,Rupp J,et al.Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with chlamydia pneumoniae[J].Circulation.2000,101:1760-1763.
[76]Monaco C,Andreakos E,Kirialddis S,et al.Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis[J].Proc Natl Pcad Sci USA,2004,101:5634-5639.
[77]徐祥.核因子κB的结构和功能研究进展[J].细胞与分子免疫学杂志.2002,18:92-95.
[78]张刚.NFκB及其相关分子研究进展[J].国外医学(临床生物化学与检验学分册).2002,23:257-259.
[79]Fan H,Sun B,Gu Q,et al.Oxygen radicals trigger activation of NF-kappaB and AP-1 and upregulation of ICAM-1 in reperfused canine heart[J].Am J Physiol Heart Circ Physiol.2002,282:1778-1786.
[80]May MJ,Ghosh S.Signal transduction through NFκB[J].Immunol Today.1998,19:80-88.
[81]高顺宗,卓晶明,董波.核转录因子与动脉粥样硬化关系的研究进展[J].中 华老年医学杂志.2004,23:356-357.
[82]Mireille D,Makio H,Chen Y,et al.Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation[J].Science.1999,284:309-313.
[83]Alexander H,Andre L,Martin L,et al.The IκB-NFκB signaling modulez:temporal control and selective gene activation[J].Science.2002,298:1241-1245.
[84]吴丽娟,蒋建新,朱佩芳等.NFκB活化与机体的免疫应答[J].生命的化学.2003,23:384-386.
[85]编辑部述评.高密度脂蛋白也可能变成“坏”的脂蛋白[J].高血压杂志.2006,14:2-4.
[86]Navab M,Anantharamaiah GM,Reddy ST,et al.Mechanisms of disease:proatherogenic HDL—an evolving field[J].Nat Clin Pract Endocrinol Metab.2006,2:504-511.
[87]Dodani S.Excess coronary artery disease risk in South Asian immigrants:Can dysfunctional high-density lipoprotein explain increased risk?[J]Vasc Health Risk Manag.2008,4:953-961.
[88]van Leeuwen HJ,Heezius EC,Dallinga GM,et al.Lipoprotein metabolism in patients with severe sepsis[J].Crit Care Med.2003,31:1359-1366.
[89]Chenaud C,Merlani PG,Roux-Lombard P,et al.Low apolipoprotem A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation[J].Crit Care Med.2004,32:632-637.
[90]Carpintero R,Pineiro M,Andres M,et al.The concentration of Apolipoprotein A-I decreases during experimentally induced acute phase processes in pigs[J].Infect Immun.2005,73:3184-3187.
[91]Hubsch AP,Casas AT,Doran JE.Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteraemia models[J].J Lab Clin Med.1995,126:548-558.
[92]Madan B,Ghosh BC.Diferuloylmethane inhibits neutrophil infiltration and improves survival of mice in high dose endotoxin shock[J].Shock.2003,19:91-96.
[93]Pajkrt D,Doran JE,Koster F,et al.Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia[J].J Exp Med.1996,184:1601-1608.
[94]Brewer HB Jr,Ronan R,Meng MS,et al.Isolation and characterization of apolipoproteins A-I, A-II, and A-IV[J]. Methods Enzymol. 1986,128:223-235.
[95] Sirtori CR, Calabresi L, Franceschini G Recombinant apolipoproteins for the treatment of vascular disease[J]. Atherosclerosis. 1999,142:29-40.
[96] Calabresi L, Vecchio G, Longhi R, et al. Molecular characterization of native and recombinant apolipoprotein A-I_(Milano) dimer. The introduction of an interchain disulfide bridge remarkably alters the physicochemical properties of apolipoprotein A-I[J]. J Biol Chem. 1994,269:32168-32174.
[97] Pajkrt D, Doran JE, Koster F, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia[J]. J Exp Med. 1996,184:1601-1608.
[98] Jonas A. Reconstitution of high-density lipoprotein[J]. Methods Enzymol. 1986,128:553-582.
[99] Calabresi L, Meng QH, Gastro GR, et al. Apolipoprotein A-I conformation in discoidal particles: evidence for alternate structures [J]. Biochemistry. 1993,32: 6477-6484.
[100] Quezado ZM, Natanson C, Banks SM, et al. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock[J]. J Pharm Exp Ther. 1995,272:604-611.
[101] Nanjee MN, Crouse JR, King JM, et al. Effects of intravenous infusion of lipid-free apo Al in humans[J]. Arterioscler Thromb Vasc Biol. 1996,16:1203-1214.
[102] Kee P, Rye KA, Taylor JL, et al. Metabolism of ApoA-I as lipid-free protein or as component of discoidal and spherical Reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbits[J]. Arterioscler Thromb Vasc Biol.2002,22:1912-1917.
[103] Troutt JS, Alborn WE, Mosior MK, et al. An Apolipoprotein A-I mimetic dose-dependently increases formation of pre-β_1 HDL in human plasma[J]. J Lipid Res. 2008,49:581-587.
[104] Rye KA, Barter PJ. Antiinflammatory actions of HDL: a new insight[J]. Arterioscler Thromb Vasc Biol. 2008,28:1890-1891.
[1]陈雅琴,赵水平.高密度脂蛋白在动脉粥样硬化发病中的双重作用[J].医学与哲学(临床决策论坛版).2008,29:46-48.
[2]Shah PK,Yano J,Reyes O,et al.High dose recombinant apolipoprotein A-I milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein deficient mice.Potential implicationsfor acute plaque stabilization[J].Circulation.2001,103:3047-3050.
[3]Lewis GF,Rader DJ.New insights into the regulation of HDL metabolism and reverse cholesterol transport[J].Circ Res.2005,96:1221-1232.
[4]Navab M,Hama SY,Cooke CJ,et al.Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein:step 1[J].J Lipid Res.2000,41:1481-1494.
[5]吴满平.ATP结合盒转运体A1介导细胞胆固醇流出及新生盘状高密度脂蛋白形成机制研究进展.中国动脉硬化杂志[J].2008,16:244-246
[6]Nissen SE,Tardif JC,Nicholl SJ,et al.Effect of torcetrapib on the progression of coronary atherosclerosis[J].N Engl J Med.2007,356:1304-1316.
[7]Phillips MC.Effiux of cholesterol from cells[J].Atherosclerosis.2000,150,suppl 2:S4.
[8]Cabana VG,Reardon CA,Feng N,et al.Serum paraoxonase:effect of the apolipoprotein composition of HDL and the acute phase response[J].J Lipid Res.2003,44:780-792.
[9]王琦光,郭志刚.高密度脂蛋白抗氧化作用及意义[J].中国分子心脏病学杂志.2005,5:635-638.
[10]Ng CJ,Shih DM,Hama SY,et al.The paraoxonase gene family and atherosclerosis[J].Free Radical Bio Med.2005,38:153-163
[11]Rizos E,Tambaki AP,Gazi I,et al.Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome[J].Prostaglandins Leukot Essent Fatty Acids.2005,72:203-209.
[12]Navab M,Hama SY,Cooke CJ,et al.Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein:step 1[J].J Lipid Res.2000,41:1481-1494.
[13]Baumberger C,Ulevitch RJ,Dayer JM.Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein[J].Pathobiology.1991,59:378-383.
[14]Emancipator K,Csako G.,Elin RJ.In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins[J].Infect Immun.1992,60:596-601.
[15]张寰,吴满平,楼滨,等.高密度脂蛋白的抗内毒素作用[J].复旦学报医学版.2003,30:474-476.
[16]Ma J,Liao XL,Lou B,et al.Role of Apolipoprotein A-I in protecting against endotoxin toxicity[J].Acta Biochim Biophys Sin.2004:36:419-249.
[17] Wurfel MM, Kunitake ST, Lichenstein H, et al. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS[J]. J Exp Med, 1994,180:1025-1035.
[18] Levels J.H., Abraham P.R., van den Ende A., van Deventer S.J.. Distribution and kinetics of lipoprotein-bound endotoxin[J]. Infect Immun. 2001,69:2821-2828.
[19] Kitchens RL, Wolfbauer G, Albers JJ, et al. Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface[J]. J Biol Chem. 1999,274:34116-34122.
[20] Wicken AJ, Knox KW. Lipoteichoic acids: a new class of bacterial antigen Membrane lipoteichoic acids can function as surface antigens of gram-positive bacteria[J]. Science. 1975,187:1161-1167.
[21] Grunfeld C, Marshall M, Shigenaga JK, et al. Lipoproteins inhibit macrophage activation by lipoteichoic acid[J]. J Lipid Res. 1999,40:245-252.
[22] Cockerill GW, Rye K-A, Gamble JR, et al. High density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules[J]. Arterioscler Thromb Vasc Biol. 1995,15:1987-1994.
[23] Cockerill GW, Huehns TY, Weerasinghe A, et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation[J]. Circulation. 2001,103: 108-112.
[24] McDonald MC, Dhadly P, Cockerill GW, et al. Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock[J]. Shock. 2003,20:551-557.
[25] Cockerill GW, McDonald MC, Mota-Filipe H, et al. High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock[J]. FASEB J. 2001,15:1941-1952.
[26] Dipiro JT, Cue JI, Richards CS, et al. Pharmacokinetics of reconstituted human high-density lipoprotein in pigs after hemorrhagic shock with resuscitation[J]. Crit Care Med. 1996,24:440-444.
[27] Thiemermann C, Patel NS, Kvale EO, et al. High density lipoprotein (HDL) reduces renal ischemia/reperfusion injury[J]. J Am Soc Nephrol. 2003,14: 1833-1843.
[28]Calabresi L,Rossoni G,Gomaraschi M,et al.High-density lipoprotein protect rat hearts from ischemia-reperfusion injury by reducing cardiac TNF-content and enhancing prostaglandin release[J].Circ Res.2003,92:330-337.
[29]Gong M,Wilson M,Kelly T,et al.HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner[J].J Clin Invest.2003,111:1579-1587.
[30]Hyka N,Dayer JM,Modoux C,et al.Apolipoprotein A-I inhibits the production of interleukin-1β and tumor necrosis factor-α by blocking contact-mediated activation of monocytes by T lymphocytes[J].Blood.2001,97:2381-2389.
[31]Liao XL,Lou B,Ma J,et al.Neutrophils activation can be diminished by apolipoprotein A-I[J].Life Sci.2005,77:325-335.
[32]彭松泉,黄全跃.高密度脂蛋白的抗血栓和促纤溶作用[J].中华老年心脑血管病杂志.2005,7:283-285.
[33]Uittenbogaard A,Shaul PW,Yuhanna IS,et al.High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae[J].J Biol Chem.2000,275:11278-11283.
[34]Cominacini L,Rigoni A,Pasini AF,et al.The bindingof oxidized Iowdensity lipoprotein ox-LDL to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide[J].J Biol Chem.2001,276:13750-13755.
[35]Cuchel M,Rader DJ.The role of high density lipoproteins in thrombosis[J].Scientific World Journal.2002,2:89-95.
[36]Laura C,Monica G,Guido F.Endothelial protection by high-density lipoproteins:from bench to bedside[J].Aterioscler Thromb Vasc Biol.2003,23:1724-1731.
[37]Tselepis AD,Chapman MJ.Inflammation,bioactive lipids and atherosclerosis:potential roles of a lipoprotein-associated phospholipase A2,platelet activating factor-acetylhydrolase[J].Atheroscler Suppl.2002,3:57-68.
[38]Ren S,Shen GX.Impact of antioxidants and HDL on glycated LDL-induced generation of fibrinolytic regulators from vascular endothelial cells[J].Aterioscler Thromb Vasc Biol.2000,20:1688-1693.
[39]Navab M,Anantharamaiah GM,Reddy ST,et al.Mechanisms of disease:proatherogenic HDL—an evolving field[J].Nat Clin Pract Endocrinol Metab.2006,2:504-511.
[40]van der Westhuyzen DR,de Beer FC,Webb NR.HDL cholesterol transport during inflammation[J].Curr Opin Lipidol.2007,18:147-151.
[41]Kitchens RL,Thompson PA,Munford RS,et al.Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins[J].J Lipid Res.2003,44:2339-2348.
[42]White HD,Simes RJ,Anderson NE,et al.Pravastatin therapy and the risk of stroke[J].N Engl J Med.2000,343:317-326.
[43]廖雪玲,马娟,楼滨,等.血浆高密度脂蛋白的组成成分在LPS诱导的急性时相反应中的变化[J].复旦大学学报.2004,31:469-472.
[44]Lewis GF,Rader DJ.New insights into the regulation of HDL metabolism and reverse cholesterol transport[J].Circ Res.2005,96:1221-1232.
[45]Rohrer L,Hersberger M,von Eckardstein A.High density lipoproteins in the intersection of diabetes mellitus,inflammation and cardiovascular disease[J].Curr Opin Lipidol.2004,15:269-278.
[46]Kontush A,Chapman MJ.Functionally defective high-density lipoprotein:a new therapeutic target at the crossroads of dyslipidemia,inflammation,and atherosclerosis[J].Pharmacol Rev.2006,58:342-374.
[2]Ross R.Atherosclerosis—an inflammatory disease[J].N Engl J Med.1999,340:115-126.
[3]van Leeuwen HJ,van Beek AP,Dallinga-Thie GM,et al[J].The role of high density lipoprotein in sepsis.Neth J Med.2001,59:102-110.
[4]张慧平.高密度脂蛋白与动脉粥样硬化和冠心病[J].中国动脉硬化杂志.2004,12:733-736.
[5]方微,张慧信,王绿娅.粘附分子、炎症与动脉粥样硬化[J].中国动脉硬化杂志.2002,10:64-66.
[6]Price MJ,Shah PK.New strategies in managing and preventing atherosclerosis:focus on HDL[J].Rev Cardiovasc Med.2002,3:129-137.
[7]Blankenhorn DH,Hodis HN.Atherosclerosis-reversal with therapy[J].West J Med.1993,159:172-179.
[8]Krause BR,Auerbach BJ.Reverse cholesterol transport and future pharmacologi -cal approaches to the treatment of atherosclerosis[J].Curr Opin Investig Drugs.2001,2:375-381.
[9]田庆印.氧化修饰脂蛋白与动脉粥样硬化[J].中国动脉硬化杂志.96,4:149-153.
[10]Wu AH,Hinds CJ,Thiemermann C.High-density lipoproteins in sepsis and septic shock:metabolism,actions,and therapeutic applications[J].Shock.2004,21:210-221.
[11]Murch O,Collin M,Hinds CJ,Yhiemermann C.Lipoproteins in inflammation and sepsis.I.Basic science[J].Intensive Care Med.2007,33:13-24.
[12]Shin WS,Szuba A,Rockson SG.The role of chemokines in human cardiovascular pathology:enhanced biological insights[J].Atherosclerosis.2002,160:91-102.
[13]Krishnaswamy G,Kelley J,Yerra L,et al.Human endothelium as a source of multifunctional cytokines:molecular regulation and possible role in human disease[J].J Interferon Cytokine Res.1999,19:91-104.
[14]Mach F.The role of chemokines in atherosclerosis[J].Curr Atheroscler Rep.2001,3:243-251.
[15]王利民.粘附分子和动脉粥样硬化[J].心血管病学进展.2005,26:494-498.
[16]王克勤.脂蛋白与动脉粥样硬化[M].北京:人民卫生出版社,1995:56.
[17]Puranik R,Bao S,Nobecourt E,et al.Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo[J].Atherosclerosis.2007,196:240-247.
[18]Thaveeratitham P,Plengpanich W,Naen-Udom W,et al.Effects of human apolipoprotein A-I on endotoxin-induced leukocyte adhesion on endothelial cells in vivo and on the growth of Escherichia coli in vitro[J].J Endotoxin Res.2007,13:58-64.
[19]Ma J,Liao XL,Lou B,et al.Role of apolipoprotein A-I in protecting against endotoxin toxicity[J].Acta Biochim Biophys Sin(Shanghai).2004,36:419-424.
[20]Jiao YL,Wu MP.Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid[J].Cytokine.2008,43:83-87
[21]Yan YJ,Li Y,Lou B,et al.Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice[J].Life Sci.2006,79,210-215.
[22]Liao XL,Lou B,Ma J,et al.Neutrophils activation can be diminished by apolipoprotein A-I[J].Life Sci.2005,77:325-335.
[23]Li Y,Dong JB,Wu MP.Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice[J].Eur J Pharmacol.2008,590:417-422.
[24]Gu SS,Shi N,Wu MP.The protective effect of ApolipoproteinA-I on myocardial ischemia-reperfusion injury in rats[J].Life Sci.2007,81:702-709.
[25]Shi N,Wu MP.Apolipoprotein A-I attenuates renal ischemia/reperfusion injury in rats[J].J Biomed Sci.2008,15:577-583.
[26]Lerch PG,F(o|¨)rtsch V,Hodler G,Bolli R.Production and characterization of a reconstituted high density lipoprotein for therapeutic applications[J].Vox Sang.1996,71:155-164.
[27]Ulrich-Merzenich G,Metzner C,Bhonde RR,et al.Simultaneous isolation of endothelial and smooth muscle cells from human umbilical artery or vein and their growth response to low-density lipoproteins[J].In Vitro Cell Dev Biol Anim.2002.38:265-272.
[28]宋今丹,章静波,张世馥,等.组织和细胞培养技术[M].北京:人民卫生出版社,2004:69.
[29]Weibel ER,Palade GE.New cytoplasmic components in arterial endothelia[J].J Cell Biol.1964,23:101-112.
[30]Wagner DD,Olmsted JB,Marder VJ.Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells[J].J Cell Biol.1982,95:355-360.
[31]Haverkate F.Levels of haemostatic factors,arteriosclerosis and cardiovascular disease[J].Vasc Pharm.2002,39:109-112.
[32]Tracy RP,Bovill EG,Yanez D,et al.Fibrinogen and factor Ⅷ,but not factor Ⅶ,are associated with measures of subclinical cardiovascular disease in the elderly:results from the cardiovascular health study[J].Arterioscler Thromb Vasc Biol.1995,15:1269-1279.
[33]Niwa K,Kado T,Sakai J,et al.The effects of a shear flow on the uptake of LDL and acetylated LDL by an EC monoculture and an EC-SMC coculture[J].Ann Biomed Engine.2004,32:537-543.
[34]Niwa K,Sakai J,Watanabe T,et al.Improved arterial wall model by coculturing vascular endothelial and smooth muscle cells[J].In Vitro Cell Dev Biol-Animal.2007,43:17-20.
[35]成安,吴满平,陈佩芳,等.高密度脂蛋白的氧化修饰的特征及对低密度脂蛋白氧化的影响[J].上海医科大学学报.1997,24:167.
[36]余灯广,高秋华,胡锦东,等.TBARS法测定胰岛素口腔喷雾剂中脂质过氧化物研究[J].分析科学学报.2005,21:78-80.
[37]Keiper T,Al-Fakhri N,Chavakis E,et al.The role of junctional adhesion molecule-C(JAM-C) in oxidized LDL-mediated leukocyte recruitment[J].FASEB J.2005,19:2078-2080.
[38]Murphy AJ,Woollard KJ,Hoang A,et al.High-density lipoprotein reduces the human monocyte inflammatory response[J].Arterioscler Thromb Vasc Biol.2008,28:2071-2077.
[39]Cobb RR,Felts KA,McKenzie TC,et al.A benzothiophene-carboxamide is a potent inhibitor of IL-1β induced VCAM-1 gene expression in human endothelial cells[J].FEBS Lett.1996,382:323-326.
[40]Tamai R,Sugawara S,Takeuchi O,et al.Synergistic effects of lipopolysaccharide and interferon-γ in inducing interleukin-8 production in human monocytic THP-1 cells is accompanied by up-regulation of CD14,Toll-like receptor 4,MD-2 and MyD88 expression[J].J Endotoxin Res.2003,9:145-153.
[41]Kimpinski K,Jelinski S,Mearow K.The anti-p75 antibody,MC192,and brain -derived neurotrophic factor inhibit nerve growth factor-dependent neurite growth from adult sensory neurons[J].Neuroscience.1999,93:253-263.
[42]彭世国,胡定远,余建华.沉淀剂浓度对测定高密度脂蛋白胆固醇的影响[J].华西医学.1999,14:473-474.
[43]Navab M,Hama SY,Hough GP,et al.A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids[J].J Lipid Res.2001,8:1308-1317.
[44]Ansell B J,Navab M,Hama S,et al.Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment[J].Circulation.2003,108:2751-2756.
[45]Fruebis J,Gonzalez V,Silvetre M,et al.Effect ofp robucol treatment on gene expression of VCAM-1,MCP-1,and M-CSF in the aortic wall of LDL receptordeficient rabbits during early atherogenesis[J].Arterioscler Thromb Vasc Biol.1997,17:1289-1302.
[46]蔡雪黎,杨德业.炎性反应因子在动脉粥样硬化中的角色[J].中国临床实用医学.2007,1:79-82.
[47]周兴建,蒋绿芝.MCP-1与胰岛素抵抗和2型糖尿病的关系[J].国际内分泌代谢杂志.2006,26:99-101.
[48]杨简.细胞黏附分子和动脉粥样硬化[J].医学综述.2006,12:1307-1309.
[49]Bella J,Kolatkar PR,Marlor CW,et al.The structure of the two aminoterminal domains of human intercellular adhesion molecule21 suggests how it functions as a rhinovirus receptor[J].Virus Res.1999,62:107-117.
[50]Sakai A,Kume N,Nishi E,et al.P-selectin and vascular cell adhesion molecule-1 are focally expression in aortas of hypercholesterolemic rabbits before intimal accumulation of macrophages and T lymphocytes[J].Arterioscler Thromb Vase Biol.1997,1'7:310-316.
[51]Cusack MR,Marber MS,Lambiase PD,et al.Systemic inflammation in unstable angina is the result of myocardial necrosis[J].J Am Coll Cardiol.2002,39:1917-1923.
[52]Babi LS,Moser B,Soler MP,et al.The interleukin-8 receptor B and CXC-chemokines can mediate transendothelial migration of human skin homing T cells[J].Eur J Immunol.1996,26:2056-2059.
[53]Mulvihill NT,Foley JB,Murphy RT,et al.Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules[J].Heart.2001,85:623-625.
[54]张红霞,刘剑刚.动脉粥样硬化发病机制和炎症反应关系研究进展[J].中国心血管杂志.2005,10:385-387
[55]刘兴.脂多糖受体的研究进展[J].国外医学临床生物化学与检验学分册.2001.22:134-137.
[56]陈理华.CD14分子的受体作用及其信号传递[J].国外医学免疫学分册.2000,23:137-140.
[57]张葵.CD14的研究进展及临床意义[J].临床检验杂志.2003,21:367-368.
[58]谢金文,万勇,余为一.CD14分子的研究进展[J].安徽农学通报,2006,12:35
[59]龚建平,韩本立.CD14在LPS介导Kuffer细胞激活中的作用[J].世界华人消化杂志.1999,79:875-877.
[60]Stephan RK,Peter AS,Robert LMl The role of Toll-like receptors in host defense against microbial infection[J].Curr Opin Immunol.2001,13:104-108.
[61]van Amersfoort ES,van Berkel TJ,Kuiper J.Receptors,mediators,and mechanisms involved in bacterial sepsis and septic shock[J].Clin Microbiol Rev.2003,16:379-414.
[62]Miyake K.Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2:unique roles for MD-2[J].Int Immunol Pharmacol.2003,3:119-128.
[63]Parviz AN,Hacker H,Mark R.Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distince cellula rcompartments[J].Eur J Immunol.2002,327:1958-1968.
[64]Normura F,Akashi S,Sakao Y,et al.Endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4expression[J].J Immunol.2000,164:3476-3479.
[65]Lorens E,Mira JP,Frees KL,et al.Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock[J].Arch Intern Med.2002,162:1028-1032
[66]Child NJ,Yang IA,Pulletz MC,et al.Polymorphismsin toll-like receptor 4 and the systemic inflammatory response syndrome[J].Biochem Soc Trans.2003,31:652-653.
[67]Gangloff M,Gay NJ.MD-2:the Toll "gatekeeper" in endotoxin signalling[J]. Trends Biochem Sci.2004,29:294-300.
[68]刘轩,魏育林.LPS受体CD14的最新研究进展[J].解剖科学进.1999,5:1-7.
[69]赵虎,周庭银.CD14的结果与功能[J].免疫学杂志.2000,16:74-76.
[70]徐也鲁.动脉粥样硬化——一种慢性炎症过程[J].中国动脉硬化杂志.2001,9:93-95.
[71]Hosono M,De Boer OJ,Vander-Wal AC,et al.Increased expression of T cell activation markers(CD25,CD26,CD30L and CD69) in atherectomy specimens of atients with unstable angina and acute myocardial infarction[J].Atherosclerosis.2003,168:73-80.
[72]范乐明.动脉粥样硬化炎症机制的再认识[J].中国动脉硬化杂志.2005,13:249-253.
[73]Hernandez-Presa M,Ortego M,Tunon J,et al.Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet[J].Cardiovasc Res.2003,57:168-177.
[74]敖启林,熊密,郝春荣,等.NFκB的活性和iNOS基因表达在低氧性肺动脉高压中的变化[J].中国病理生理杂志.2002,18:903-906.
[75]Kothe H,Dalhoff K,Rupp J,et al.Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with chlamydia pneumoniae[J].Circulation.2000,101:1760-1763.
[76]Monaco C,Andreakos E,Kirialddis S,et al.Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis[J].Proc Natl Pcad Sci USA,2004,101:5634-5639.
[77]徐祥.核因子κB的结构和功能研究进展[J].细胞与分子免疫学杂志.2002,18:92-95.
[78]张刚.NFκB及其相关分子研究进展[J].国外医学(临床生物化学与检验学分册).2002,23:257-259.
[79]Fan H,Sun B,Gu Q,et al.Oxygen radicals trigger activation of NF-kappaB and AP-1 and upregulation of ICAM-1 in reperfused canine heart[J].Am J Physiol Heart Circ Physiol.2002,282:1778-1786.
[80]May MJ,Ghosh S.Signal transduction through NFκB[J].Immunol Today.1998,19:80-88.
[81]高顺宗,卓晶明,董波.核转录因子与动脉粥样硬化关系的研究进展[J].中 华老年医学杂志.2004,23:356-357.
[82]Mireille D,Makio H,Chen Y,et al.Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation[J].Science.1999,284:309-313.
[83]Alexander H,Andre L,Martin L,et al.The IκB-NFκB signaling modulez:temporal control and selective gene activation[J].Science.2002,298:1241-1245.
[84]吴丽娟,蒋建新,朱佩芳等.NFκB活化与机体的免疫应答[J].生命的化学.2003,23:384-386.
[85]编辑部述评.高密度脂蛋白也可能变成“坏”的脂蛋白[J].高血压杂志.2006,14:2-4.
[86]Navab M,Anantharamaiah GM,Reddy ST,et al.Mechanisms of disease:proatherogenic HDL—an evolving field[J].Nat Clin Pract Endocrinol Metab.2006,2:504-511.
[87]Dodani S.Excess coronary artery disease risk in South Asian immigrants:Can dysfunctional high-density lipoprotein explain increased risk?[J]Vasc Health Risk Manag.2008,4:953-961.
[88]van Leeuwen HJ,Heezius EC,Dallinga GM,et al.Lipoprotein metabolism in patients with severe sepsis[J].Crit Care Med.2003,31:1359-1366.
[89]Chenaud C,Merlani PG,Roux-Lombard P,et al.Low apolipoprotem A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation[J].Crit Care Med.2004,32:632-637.
[90]Carpintero R,Pineiro M,Andres M,et al.The concentration of Apolipoprotein A-I decreases during experimentally induced acute phase processes in pigs[J].Infect Immun.2005,73:3184-3187.
[91]Hubsch AP,Casas AT,Doran JE.Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteraemia models[J].J Lab Clin Med.1995,126:548-558.
[92]Madan B,Ghosh BC.Diferuloylmethane inhibits neutrophil infiltration and improves survival of mice in high dose endotoxin shock[J].Shock.2003,19:91-96.
[93]Pajkrt D,Doran JE,Koster F,et al.Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia[J].J Exp Med.1996,184:1601-1608.
[94]Brewer HB Jr,Ronan R,Meng MS,et al.Isolation and characterization of apolipoproteins A-I, A-II, and A-IV[J]. Methods Enzymol. 1986,128:223-235.
[95] Sirtori CR, Calabresi L, Franceschini G Recombinant apolipoproteins for the treatment of vascular disease[J]. Atherosclerosis. 1999,142:29-40.
[96] Calabresi L, Vecchio G, Longhi R, et al. Molecular characterization of native and recombinant apolipoprotein A-I_(Milano) dimer. The introduction of an interchain disulfide bridge remarkably alters the physicochemical properties of apolipoprotein A-I[J]. J Biol Chem. 1994,269:32168-32174.
[97] Pajkrt D, Doran JE, Koster F, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia[J]. J Exp Med. 1996,184:1601-1608.
[98] Jonas A. Reconstitution of high-density lipoprotein[J]. Methods Enzymol. 1986,128:553-582.
[99] Calabresi L, Meng QH, Gastro GR, et al. Apolipoprotein A-I conformation in discoidal particles: evidence for alternate structures [J]. Biochemistry. 1993,32: 6477-6484.
[100] Quezado ZM, Natanson C, Banks SM, et al. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock[J]. J Pharm Exp Ther. 1995,272:604-611.
[101] Nanjee MN, Crouse JR, King JM, et al. Effects of intravenous infusion of lipid-free apo Al in humans[J]. Arterioscler Thromb Vasc Biol. 1996,16:1203-1214.
[102] Kee P, Rye KA, Taylor JL, et al. Metabolism of ApoA-I as lipid-free protein or as component of discoidal and spherical Reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbits[J]. Arterioscler Thromb Vasc Biol.2002,22:1912-1917.
[103] Troutt JS, Alborn WE, Mosior MK, et al. An Apolipoprotein A-I mimetic dose-dependently increases formation of pre-β_1 HDL in human plasma[J]. J Lipid Res. 2008,49:581-587.
[104] Rye KA, Barter PJ. Antiinflammatory actions of HDL: a new insight[J]. Arterioscler Thromb Vasc Biol. 2008,28:1890-1891.
[1]陈雅琴,赵水平.高密度脂蛋白在动脉粥样硬化发病中的双重作用[J].医学与哲学(临床决策论坛版).2008,29:46-48.
[2]Shah PK,Yano J,Reyes O,et al.High dose recombinant apolipoprotein A-I milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein deficient mice.Potential implicationsfor acute plaque stabilization[J].Circulation.2001,103:3047-3050.
[3]Lewis GF,Rader DJ.New insights into the regulation of HDL metabolism and reverse cholesterol transport[J].Circ Res.2005,96:1221-1232.
[4]Navab M,Hama SY,Cooke CJ,et al.Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein:step 1[J].J Lipid Res.2000,41:1481-1494.
[5]吴满平.ATP结合盒转运体A1介导细胞胆固醇流出及新生盘状高密度脂蛋白形成机制研究进展.中国动脉硬化杂志[J].2008,16:244-246
[6]Nissen SE,Tardif JC,Nicholl SJ,et al.Effect of torcetrapib on the progression of coronary atherosclerosis[J].N Engl J Med.2007,356:1304-1316.
[7]Phillips MC.Effiux of cholesterol from cells[J].Atherosclerosis.2000,150,suppl 2:S4.
[8]Cabana VG,Reardon CA,Feng N,et al.Serum paraoxonase:effect of the apolipoprotein composition of HDL and the acute phase response[J].J Lipid Res.2003,44:780-792.
[9]王琦光,郭志刚.高密度脂蛋白抗氧化作用及意义[J].中国分子心脏病学杂志.2005,5:635-638.
[10]Ng CJ,Shih DM,Hama SY,et al.The paraoxonase gene family and atherosclerosis[J].Free Radical Bio Med.2005,38:153-163
[11]Rizos E,Tambaki AP,Gazi I,et al.Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome[J].Prostaglandins Leukot Essent Fatty Acids.2005,72:203-209.
[12]Navab M,Hama SY,Cooke CJ,et al.Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein:step 1[J].J Lipid Res.2000,41:1481-1494.
[13]Baumberger C,Ulevitch RJ,Dayer JM.Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein[J].Pathobiology.1991,59:378-383.
[14]Emancipator K,Csako G.,Elin RJ.In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins[J].Infect Immun.1992,60:596-601.
[15]张寰,吴满平,楼滨,等.高密度脂蛋白的抗内毒素作用[J].复旦学报医学版.2003,30:474-476.
[16]Ma J,Liao XL,Lou B,et al.Role of Apolipoprotein A-I in protecting against endotoxin toxicity[J].Acta Biochim Biophys Sin.2004:36:419-249.
[17] Wurfel MM, Kunitake ST, Lichenstein H, et al. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS[J]. J Exp Med, 1994,180:1025-1035.
[18] Levels J.H., Abraham P.R., van den Ende A., van Deventer S.J.. Distribution and kinetics of lipoprotein-bound endotoxin[J]. Infect Immun. 2001,69:2821-2828.
[19] Kitchens RL, Wolfbauer G, Albers JJ, et al. Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface[J]. J Biol Chem. 1999,274:34116-34122.
[20] Wicken AJ, Knox KW. Lipoteichoic acids: a new class of bacterial antigen Membrane lipoteichoic acids can function as surface antigens of gram-positive bacteria[J]. Science. 1975,187:1161-1167.
[21] Grunfeld C, Marshall M, Shigenaga JK, et al. Lipoproteins inhibit macrophage activation by lipoteichoic acid[J]. J Lipid Res. 1999,40:245-252.
[22] Cockerill GW, Rye K-A, Gamble JR, et al. High density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules[J]. Arterioscler Thromb Vasc Biol. 1995,15:1987-1994.
[23] Cockerill GW, Huehns TY, Weerasinghe A, et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation[J]. Circulation. 2001,103: 108-112.
[24] McDonald MC, Dhadly P, Cockerill GW, et al. Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock[J]. Shock. 2003,20:551-557.
[25] Cockerill GW, McDonald MC, Mota-Filipe H, et al. High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock[J]. FASEB J. 2001,15:1941-1952.
[26] Dipiro JT, Cue JI, Richards CS, et al. Pharmacokinetics of reconstituted human high-density lipoprotein in pigs after hemorrhagic shock with resuscitation[J]. Crit Care Med. 1996,24:440-444.
[27] Thiemermann C, Patel NS, Kvale EO, et al. High density lipoprotein (HDL) reduces renal ischemia/reperfusion injury[J]. J Am Soc Nephrol. 2003,14: 1833-1843.
[28]Calabresi L,Rossoni G,Gomaraschi M,et al.High-density lipoprotein protect rat hearts from ischemia-reperfusion injury by reducing cardiac TNF-content and enhancing prostaglandin release[J].Circ Res.2003,92:330-337.
[29]Gong M,Wilson M,Kelly T,et al.HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner[J].J Clin Invest.2003,111:1579-1587.
[30]Hyka N,Dayer JM,Modoux C,et al.Apolipoprotein A-I inhibits the production of interleukin-1β and tumor necrosis factor-α by blocking contact-mediated activation of monocytes by T lymphocytes[J].Blood.2001,97:2381-2389.
[31]Liao XL,Lou B,Ma J,et al.Neutrophils activation can be diminished by apolipoprotein A-I[J].Life Sci.2005,77:325-335.
[32]彭松泉,黄全跃.高密度脂蛋白的抗血栓和促纤溶作用[J].中华老年心脑血管病杂志.2005,7:283-285.
[33]Uittenbogaard A,Shaul PW,Yuhanna IS,et al.High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae[J].J Biol Chem.2000,275:11278-11283.
[34]Cominacini L,Rigoni A,Pasini AF,et al.The bindingof oxidized Iowdensity lipoprotein ox-LDL to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide[J].J Biol Chem.2001,276:13750-13755.
[35]Cuchel M,Rader DJ.The role of high density lipoproteins in thrombosis[J].Scientific World Journal.2002,2:89-95.
[36]Laura C,Monica G,Guido F.Endothelial protection by high-density lipoproteins:from bench to bedside[J].Aterioscler Thromb Vasc Biol.2003,23:1724-1731.
[37]Tselepis AD,Chapman MJ.Inflammation,bioactive lipids and atherosclerosis:potential roles of a lipoprotein-associated phospholipase A2,platelet activating factor-acetylhydrolase[J].Atheroscler Suppl.2002,3:57-68.
[38]Ren S,Shen GX.Impact of antioxidants and HDL on glycated LDL-induced generation of fibrinolytic regulators from vascular endothelial cells[J].Aterioscler Thromb Vasc Biol.2000,20:1688-1693.
[39]Navab M,Anantharamaiah GM,Reddy ST,et al.Mechanisms of disease:proatherogenic HDL—an evolving field[J].Nat Clin Pract Endocrinol Metab.2006,2:504-511.
[40]van der Westhuyzen DR,de Beer FC,Webb NR.HDL cholesterol transport during inflammation[J].Curr Opin Lipidol.2007,18:147-151.
[41]Kitchens RL,Thompson PA,Munford RS,et al.Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins[J].J Lipid Res.2003,44:2339-2348.
[42]White HD,Simes RJ,Anderson NE,et al.Pravastatin therapy and the risk of stroke[J].N Engl J Med.2000,343:317-326.
[43]廖雪玲,马娟,楼滨,等.血浆高密度脂蛋白的组成成分在LPS诱导的急性时相反应中的变化[J].复旦大学学报.2004,31:469-472.
[44]Lewis GF,Rader DJ.New insights into the regulation of HDL metabolism and reverse cholesterol transport[J].Circ Res.2005,96:1221-1232.
[45]Rohrer L,Hersberger M,von Eckardstein A.High density lipoproteins in the intersection of diabetes mellitus,inflammation and cardiovascular disease[J].Curr Opin Lipidol.2004,15:269-278.
[46]Kontush A,Chapman MJ.Functionally defective high-density lipoprotein:a new therapeutic target at the crossroads of dyslipidemia,inflammation,and atherosclerosis[J].Pharmacol Rev.2006,58:342-374.